Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been assigned a consensus recommendat...
Celldex Therapeutics (NASDAQ:CLDX) Trading Down 5.5% - Time to Sell?...
Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Research analysts at Lifesci Capital issued...
Significant Improvements in Angioedema Symptoms Highlight Barzolvolimab's Potential in CSU Treatment...
HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today anno...